Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPSTAHT: PCC vs Standard Transfusion in Heart Transplant
NCT03341156Phase 3Terminated
- Sponsor
- University of Maryland, Baltimore
- Start
- Jul 2018
- Primary completion
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of coagulation factor X human in hemorrhage and coagulopathy (2 arms), sponsored by University of Maryland, Baltimore. Primary endpoint: Amount of Chest Tube Drainage at 24 hours. Started Jul 2018; status: terminated.
02
Drugs
coagulation factor X human
03
Conditions
hemorrhagecoagulopathy
Beyond the preview
Go deeper on NCT03341156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03341156.